Evidence map›Paper›PMID 41269916›Full record

Trial reportJournal of Parkinson's disease2026

Roberto Cilia, Momodou Cham, Vida Obese, Albert Akpalu, Emanuele Cereda, Elikem Ame-Bruce, Ruth Laryea, Serena Caronni, Fred Stephen Sarfo, Francesca Del Sorbo and 2 more

Abstract readMulticenter StudyRandomized Controlled TrialClinical Trial, Phase II
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of Parkinson's disease, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. "Journal of Parkinson's disease · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Roberto CiliaParkinson and Movement Disorders Unit, Department of Clinical Neurosciences, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy.ORCID 0000-0002-1990-1939
Momodou ChamRichard Novati Catholic Hospital, Sogakope, Ghana.
Vida ObeseKomfo Anokye Teaching Hospital, Kumasi, Ghana.
Albert AkpaluKorle Bu Teaching Hospital, Accra, Ghana.
Emanuele CeredaClinical Nutrition and Dietetics Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy.
Elikem Ame-BruceRichard Novati Catholic Hospital, Sogakope, Ghana.
Ruth LaryeaKorle Bu Teaching Hospital, Accra, Ghana.ORCID 0000-0002-7963-6145
Serena CaronniFondazione Pezzoli per la Malattia di Parkinson, Milan, Italy.
Fred Stephen SarfoKomfo Anokye Teaching Hospital, Kumasi, Ghana.
Francesca Del SorboParkinson Institute, ASST Gaetano Pini-CTO, Milan, Italy.
Stanley FahnColumbia University College of Physicians and Surgeons, New York, NY, USA.
Gianni PezzoliFondazione Pezzoli per la Malattia di Parkinson, Milan, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BackgroundParkinson's disease (PD) causes disability and premature mortality if untreated. Limited access to levodopa in low- and middle-income countries leaves many patients undertreated.

Indexed as

Antiparkinson AgentsLevodopaMucunaParkinson DiseasePhytotherapyPlant ExtractsAfrica South of the SaharaAgedFemaleHumansMaleMiddle AgedQuality of LifeTreatment OutcomeAntiparkinson AgentsLevodopaPlant ExtractsaccessibilityequalitylevodopaMucuna pruriensParkinson's disease

Identifiers

PMID41269916
PMCPMC13347555

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.